By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI JPM, we had 56 companies participate in the Innovator’s Pitch Challenge (IPC). These finalist companies pitched to an audience and fielded questions from an investor judges panel, as well as exhibited a poster showcasing their technology at the conference.
Registered RESI attendees (startup executives, early-stage investors, and industry experts), ‘invest’ or vote for their favorite IPC company with RESI cash provided, based on the pitch company’s poster board displayed at RESI’s exhibit hall and their performance in the Q&A portion of their pitch session.
Life Science Nation is pleased to share the winners who received the most votes during the RESI JPM. Congratulations to the winners!
1st Place – Cardathea
Cardathea has the potential to disrupt the $16B cardiac pacing systems market by making fast, easy, reliable “conduction system pacing” (CSP, considered the gold standard by rhythm societies around the world but currently only done ~1% of the time due to lack of needed tools) finally possible with its EFI (electric field imaging) system. A pacing system manufacturer with exclusive access to our system would have an unfair advantage as pacing practice shifts from current methods to CSP. A 5% shift in market share is worth >$1B to a pacing system acquirer … not counting revenue from our system. Cardathea has already used its non-invasive imaging and guidance system in 8 pigs and 14 people.
Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Rick Berenson, Founder & Serial Entrepreneur, Cardathea | Brian Craig, Founder & Medical Device Commercialization Wiz, Cardathea
2nd Place – Convergence Medical
Convergence Medical Pty Ltd is a Brisbane based medical device company, focused on the advancing arthroscopy with design and development of the world’s first arthroscopic robot (the V01 – Arthroscopic Surgical Robot).
We exist to address the significant problems in arthroscopic surgery, improving the lives of the 50 million patients treated every year and the 30 thousand surgeons who perform these operations.
The V01 is developed to change practice by providing ridged stability and robotic precision, power by an immersive and intuitive interface making operations simpler and more efficient. These innovations are designed to help the 70% of surgeons who perform these procedures and regularly experience significant muscular skeletal pain, the 30% of surgeons forced to retire early, the third of surgeons that state they don’t feel confident with their abilities and the 40% of patients which have observable damage during an operation.
Cameron Hurlburt, Director of Business Development – West Coast (US), LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Chris Jeffery, CEO, Convergence Medical
3rd Place – Gelomics
Gelomics fast-tracks drug development by enabling pharmaceutical companies to grow human tissues as an ethical, economical, and highly predictive alternative to animal experiments. The company has validated its MVP with 200+ paying customers in 22 markets, achieving >30% MoM revenue growth, >80% demo-to-sales conversion, and >$500,000 in sales, all through self-funding efforts. In Q4 2023, Gelomics closed its $2m pre-seed round and secured an additional $1.15m in non-dilutive funding to progress its R&D pipeline and enter the Drug Development Technology market, addressing a TAM of >$100bn. The company is seeking to expand its network of US-based venture capital and strategic partners in preparation for its next major investment round and the strategic entry into the US market.
Momo Yamamoto, Investor Research Analyst, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Christoph Meinert, PhD, CEO & Co-Founder, Gelomics
Next Phase Newsletter 
Leave a comment